Human health impacts of PFAS exposure: A second-order meta-analysis
Abstract
Per- and polyfluoroalkyl substances (PFAS) are highly persistent synthetic chemicals with pervasive human exposure. Numerous meta-analyses have synthesised results on the association between PFAS exposure and human health, yet findings remain fragmented and often inconsistent across compounds, outcomes, and studies. We assessed the magnitude and consistency of associations between PFAS exposure and human health outcomes by integrating evidence from 23 meta-analyses encompassing 161 primary studies. PFAS exposure was associated with a 5% increase in the odds of adverse health outcomes (overall OR = 1.05, 95% CI: 1.03–1.08) and a moderate heterogeneity (overall I² = 64%, 95% CI: 42–78%). Perfluorobutanesulfonic acid (PFBS) showed the largest and most consistent association among chemicals (OR = 1.30, I² = 38.1%), endocrine diseases showed the strongest association among health outcomes (OR = 1.11, I² = 61.7%), and pregnancy-related outcomes showed the highest consistency (OR = 1.04, I² = 35.9%). The widespread nature of PFAS exposure means even small relative risks could translate into substantial population-level burdens. These findings strengthen the evidence base for regulatory measures, highlight vulnerable health domains, and identify priority areas for further research, particularly for understudied compounds and outcomes.
Related
- Software Application Profile: A real-time surveillance system for monitoring heat exposure and its health impacts - presenting the Rio de Janeiro Heat Dashboard
- Occurrence and Health Risk Assessment of Organophosphate Esters in Seafood from Southeastern China: Impacts of Cooking Methods and Dietary Exposure.
- Review of human health exposure assessment frameworks in the United States and development of a unified framework for exposure assessment practitioners
- Human biomonitoring of occupational benzene exposure among petroleum-exposed workers in nigeria and its implications for public health surveillance
- Impacts of long-term climate change on human health: a global scoping review of quantitative research
BibTeX
@misc{ricolfi2026human,
title = {{Human health impacts of PFAS exposure: A second-order meta-analysis}},
author = {Lorenzo Ricolfi and Yefeng Yang and Kyle Morrison and Niki Marjerrison and Marcin W. Wojewodzic and Malgorzata Lagisz and Shinichi Nakagawa},
howpublished = {EarthArXiv},
year = {2026},
month = oct,
doi = {10.31223/x5wj7n},
url = {https://eartharxiv.org/repository/view/15355/},
note = {CC BY 4.0},
}
RIS
TY - UNPB
TI - Human health impacts of PFAS exposure: A second-order meta-analysis
AU - Lorenzo Ricolfi
AU - Yefeng Yang
AU - Kyle Morrison
AU - Niki Marjerrison
AU - Marcin W. Wojewodzic
AU - Malgorzata Lagisz
AU - Shinichi Nakagawa
PY - 2026
DA - 2026/10/04
PB - EarthArXiv
DO - 10.31223/x5wj7n
UR - https://eartharxiv.org/repository/view/15355/
AB - Per- and polyfluoroalkyl substances (PFAS) are highly persistent synthetic chemicals with pervasive human exposure. Numerous meta-analyses have synthesised results on the association between PFAS exposure and human health, yet findings remain fragmented and often inconsistent across compounds, outcomes, and studies. We assessed the magnitude and consistency of associations between PFAS exposure and human health outcomes by integrating evidence from 23 meta-analyses encompassing 161 primary studies. PFAS exposure was associated with a 5% increase in the odds of adverse health outcomes (overall OR = 1.05, 95% CI: 1.03–1.08) and a moderate heterogeneity (overall I² = 64%, 95% CI: 42–78%). Perfluorobutanesulfonic acid (PFBS) showed the largest and most consistent association among chemicals (OR = 1.30, I² = 38.1%), endocrine diseases showed the strongest association among health outcomes (OR = 1.11, I² = 61.7%), and pregnancy-related outcomes showed the highest consistency (OR = 1.04, I² = 35.9%). The widespread nature of PFAS exposure means even small relative risks could translate into substantial population-level burdens. These findings strengthen the evidence base for regulatory measures, highlight vulnerable health domains, and identify priority areas for further research, particularly for understudied compounds and outcomes.
ER -